One of Pogust Goodhead’s Partners, Mike Daly, spoke with The Legal Intelligencer, the oldest daily law journal published in the United States, last week about our US case against Injectafer.
Injectafer and HPP
The drug Injectafer (ferric carboxymaltose) is an iron replacement product designed to work quickly to restore iron levels. However, one of the most severe and previously unwarned of side effects of taking Injectafer is Severe Hypophosphatemia and the impact on one’s health.
As a condition, HPP causes your blood to have a low level of phosphorous, which can cause an array of health issues, including muscle weakness, fatigue, seizures, comas, osteomalacia, heart failure, respiratory failure, and more.
Represented by Pogust Goodhead, Injectafer patient Katherine Crockett was one of the first cases to be filed in Philadelphia state court in 2019 and was the first Injectafer case filed in the country and currently is being litigated in federal court in Philadelphia.
Comment from Pogust Goodhead
Mike told law.com: “We look forward to the opportunity to try the first Injectafer pharmaceutical case in the country.”
He continued: “This trial is the first step in bringing justice to all of the people who have suffered needlessly due to the decisions made by these pharmaceutical companies to hide the truth and put profits over the health of Iron-deficiency anemia patients.”
Clinical studies on Injectafer
Clinical studies involving Injectafer overwhelmingly point to Injectafer’s propensity to cause hypophosphatemia and severe hypophosphatemia at rates drastically higher than its competitor iron supplements.
Notably, Injectafer does not warn about severe hypophosphatemia, and historically the label downplayed the severity of clinical implications from Severe Hypophosphatemia, and still misleadingly refers to the hypophosphatemia experienced after Injectafer use as ‘transient’, when it is, in fact, often persistent and harmful.
Even when acute, severe hypophosphatemia can cause serious and potentially life-threatening injurys.
The chemical compound ferric carboxymaltose is sold outside of the United States under the trade name Ferinject, and is manufactured and distributed by one of the defendants in the US action, Swiss pharmaceutical giant Vifor Pharma (which was recently acquired by Australian company CSL Limited).
Subscribers can read the full article by Aleeza Furman here: law.com/thelegalintelligencer/2022/09/19/judge-schedules-first-trial-in-mounting-litigation-over-iron-supplement/